UK markets closed

Editas Medicine, Inc. (0IFK.L)

LSE - LSE Delayed price. Currency in USD
Add to watchlist
34.23-1.52 (-4.25%)
At close: 3:02PM BST
Full screen
Loading interactive chart…
  • Editas Medicine, Inc. (EDIT) Q1 2021 Earnings Call Transcript
    Motley Fool

    Editas Medicine, Inc. (EDIT) Q1 2021 Earnings Call Transcript

    Earlier this morning, we issued a press release providing our financial results and corporate updates for the first quarter of 2021. As a reminder, various remarks that we make during this call about the company's future expectations, plans, and prospects constitute forward-looking statements for purposes of the Safe Harbor provisions under the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including those discussed in the Risk Factors section of our most recent annual report on Form 10-K, which is on file with the SEC.

  • What Really Mattered With Editas Medicine's Q1 Update
    Motley Fool

    What Really Mattered With Editas Medicine's Q1 Update

    Editas Medicine (NASDAQ: EDIT) entered 2021 with tremendous momentum. The company announced a Q1 net loss of $56.7 million, or $0.86 per share, based on generally accepted accounting principles (GAAP). In the prior-year period, Editas posted a GAAP net loss of $37.7 million, or $0.69 per share.

  • Editas (EDIT) Q1 Earnings Miss Estimates, Revenues Beat
    Zacks

    Editas (EDIT) Q1 Earnings Miss Estimates, Revenues Beat

    Editas (EDIT) reports wider-than-expected loss in the first quarter of 2021 while revenues beat estimates. Pipeline development remains in focus for the company.